Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Brain Diseases » Dementia
Psychiatry and Psychology [F] » Mental Disorders [F03] » Neurocognitive Disorders » Dementia
Description
An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. MeSH
Hierarchy View
Subtype Terms (10)
AIDS Dementia Complex
18 drugs (15 approved, 3 experimental)
Alzheimer Disease
609 drugs (197 approved, 412 experimental)
Aphasia, Primary Progressive
4 drugs (2 approved, 2 experimental)
Creutzfeldt-Jakob Syndrome
1 experimental drug
Dementia, Vascular
45 drugs (26 approved, 19 experimental)
Diffuse Neurofibrillary Tangles with Calcification
Frontotemporal Lobar Degeneration
3 approved drugs
Huntington Disease
83 drugs (42 approved, 41 experimental)
Lewy Body Disease
36 drugs (19 approved, 17 experimental)
Phase 4 Indicated Drugs (45)
Phase 3 Indicated Drugs (85)
Phase 2 Indicated Drugs (34)
Phase 1 Indicated Drugs (12)
Other Experimental Indicated Drugs (22)
Organization Involved with Phase 4 Indications (60)
American Legion of Iowa Foundation
Chinese University of Hong Kong
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
Organization Involved with Phase 3 Indications (87)
Accelerating Medicines Partnership
Antic Hospital Sant Jaume i Santa Magdalena
Badalona Hospital Germans Trias i Pujol
Hospital de la Santa Creu, Tortosa
Hospital Universitario de Getafe
Hospital Virgen del Valle (Toledo)
Lancashire Teaching Hospitals NHS Foundation Trust
Medical University of South Carolina
National Institute of Allergy and Infectious Diseases (NIAID)
Philipps University of Marburg
Shijiazhuang Pharma Group (CSPC)
Shineway Pharmaceutical Co.,Ltd
Tuscaloosa Research & Education Advancement Corporation (TREAC)
Universidad Autonoma de Barcelona
Organization Involved with Phase 2 Indications (108)
A2 Healthcare Taiwan Corporation
Assistive Technology Clinic, Canada
Beijing Compete Pharmaceutical Co., Ltd.
Canadian Institutes of Health Research (CIHR)
Chase Pharmaceuticals Corporation
Chengdu University of Traditional Chinese Medicines
Eastern Virginia Medical School
First People's Hospital of Chenzhou
Hospital of Traditional Chinese and Western Medicine of Jilin Province
Michael J. Fox Foundation for Parkinson's Research
National Center for Complementary and Integrative Health (NCCIH)
National Cheng Kung University
National Institutes of Health (NIH)
Oregon Health and Science University
Oriental Neurosurgery Evidence-Based-Study Team
Practitioners Alliance Network
Queen Elizabeth Hospital NHS Foundation Trust
Saskatchewan Health Research Foundation
Shanghai Hutchison Pharmaceuticals Limited
Shanghai University of Traditional Chinese Medicine
Organization Involved with Phase 1 Indications (18)
Organization Involved with Other Experimental Indications (18)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
